Yazılar

Health Advocates Demand Lower Prices for Mpox Tests from Cepheid

/in /tarafından

Global health advocates are urging diagnostics firm Cepheid to slash the price of its GeneXpert mpox test from $20 to $5 per test. This reduction, they argue, is critical to combat low testing rates in poorer countries like the Democratic Republic of Congo (DRC), which is among the hardest hit by the mpox outbreak.

Current Challenges

  • High Test Costs: Cepheid’s GeneXpert test is one of three World Health Organization (WHO)-approved diagnostics for emergency mpox testing. However, its current pricing is unaffordable for low-income nations, particularly in Africa.
  • Rising Cases in Africa: The WHO reported an overall increase in mpox cases across Africa, with some stabilization in Congo. Yet, inadequate testing infrastructure hampers confirmation of cases, limiting effective responses.

Advocacy Efforts

  • A coalition of health groups, including Public Citizen and Médecins Sans Frontières, sent a letter to Cepheid and its parent company, Danaher. They are pressing for a price reduction to $5 and prioritization of supplies to African nations.
  • Advocates argue that Cepheid’s existing network of diagnostic machines in Africa, widely used for tuberculosis testing, could be leveraged for mpox diagnostics if costs are reduced.

Cepheid’s Response

  • Cepheid stated it has ramped up production of its mpox test to meet urgent demands, particularly following requests from the WHO.
  • The company claims to offer “significant” discounts through an access program for orders placed via WHO and related organizations, but has not disclosed specific pricing details.

Historical Precedent and Cost Analysis

  • In 2022, Danaher reduced prices for its tuberculosis tests to $7.97 after similar activist campaigns. Advocates argue that mpox tests could be produced for less than $5, based on research and cost analyses.
  • Public Citizen’s Peter Maybarduk emphasized that the recent WHO approval of Cepheid’s mpox test offers an opportunity to expand testing globally, stating, “Lower prices would help health agencies meet the moment.”

Conclusion

Lowering the price of mpox diagnostic tests is crucial to managing outbreaks in vulnerable regions. Cepheid’s actions in response to the advocacy push will determine the extent to which testing can be scaled up in poorer countries, especially as the virus continues to pose significant health challenges in Africa.

 

India Detects First Case of Highly Contagious Mpox Clade 1b Variant in Kerala

/in /tarafından

Kerala Confirms India’s Initial Mpox Clade 1b Infection in a 38-Year-Old Male Patient. Devamını Oku

Philippines Reports First Mpox Case of the Year, Awaiting Strain Identification

/in /tarafından

The Philippines has identified its first mpox case of the year, marking the first occurrence since December 2023. The patient, a 33-year-old Filipino male with no recent travel history outside the country, is currently under observation as health officials await sequencing results to determine the specific strain of the virus. The Department of Health (DOH) has stated that symptoms began over a week ago, starting with a fever, followed by the appearance of a distinct rash across various parts of the body, including the face, back, groin, and soles.

This case adds to the 10 laboratory-confirmed cases of mpox reported by the Philippines since July 2022. Mpox, caused by the monkeypox virus, typically presents with flu-like symptoms and pus-filled lesions, and while generally mild, it can pose serious risks, particularly for children, pregnant women, and individuals with compromised immune systems, such as those living with HIV.

Globally, mpox has been a growing concern, with the World Health Organization (WHO) recently declaring it a global public health emergency. The alarm was raised following an outbreak in the Democratic Republic of Congo that quickly spread to neighboring countries. A new variant of the virus, which appears to spread more easily through close contact, has heightened these concerns. Recent reports have confirmed cases of this variant in Sweden, linked to the African outbreak, and in Pakistan, where at least one case was detected in a patient returning from a Gulf country.

As health authorities in the Philippines and around the world continue to monitor the situation, there is an urgent need for timely identification of the virus strain and effective containment measures. This ongoing vigilance is critical as the global community grapples with the challenges posed by emerging infectious diseases. The latest case in the Philippines underscores the importance of continued public health surveillance and preparedness in addressing potential outbreaks, ensuring that responses are swift and informed by the most up-to-date scientific knowledge.